文献速递消化道出血消化内镜

选择性5-羟色胺受体抑制剂的使用与消化性溃疡出血内镜难治性出血、再出血或死亡率风险增加无关

The use of selective serotonin receptor inhibitors (SSRIs) is not associated with increased risk of endoscopy-refractory bleeding, rebleeding or mortality in peptic ulcer bleeding.
PubMed 文献 · Aliment Pharmacol Ther · 2017-05-23

该研究基于丹麦2006-2014年全国性队列中连续收治的消化性溃疡出血患者数据,采用逻辑回归分析校正预设混杂因素。共纳入14343例患者,结果显示使用选择性5-羟色胺受体抑制剂(SSRIs)与内镜难治性出血、再出血或30天死亡率风险增加均无关。

要点

  • 使用SSRIs与内镜难治性出血风险无关(OR 1.03,95%CI 0.79-1.33)。
  • 使用SSRIs与再出血风险无关(OR 0.96,95%CI 0.83-1.11)。
  • 使用SSRIs与30天死亡率风险无关(OR 1.01,95%CI 0.85-1.19)。

核心结论

  • 根据本研究数据,使用SSRIs不影响消化性溃疡出血患者内镜难治性出血、再出血或30天死亡率的风险。

研究设计与样本

  • 全国性队列研究,基于丹麦2006-2014年连续收治的消化性溃疡出血患者的前瞻性收集数据,共纳入14343例患者,采用逻辑回归分析校正预设混杂因素。

主要发现

  • 校正后,使用SSRIs与内镜难治性出血风险无关(OR 1.03,95%CI 0.79-1.33)。
  • 校正后,使用SSRIs与再出血风险无关(OR 0.96,95%CI 0.83-1.11)。
  • 校正后,使用SSRIs与30天死亡率风险无关(OR 1.01,95%CI 0.85-1.19)。
  • 敏感性和亚组分析支持上述发现。

关键数值与推荐

  • 内镜难治性出血:OR 1.03(95%CI 0.79-1.33)。
  • 再出血:OR 0.96(95%CI 0.83-1.11)。
  • 30天死亡率:OR 1.01(95%CI 0.85-1.19)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Observational studies have consistently shown an increased risk of upper gastrointestinal bleeding in users of selective serotonin receptor inhibitors (SSRIs), probably explained by their inhibition of platelet aggregation. Therefore, treatment with SSRIs is often temporarily withheld in patients with peptic ulcer bleeding. However, abrupt discontinuation of SSRIs is associated with development of withdrawal symptoms in one-third of patients. Further data are needed to clarify whether treatment with SSRIs is associated with poor outcomes, which would support temporary discontinuation of treatment. AIM: To identify if treatment with SSRIs is associated with increased risk of: (1) endoscopy-refractory bleeding, (2) rebleeding or (3) 30-day mortality due to peptic ulcer bleeding. METHODS: A nationwide cohort study. Analyses were performed on prospectively collected data on consecutive patients admitted to hospital with peptic ulcer bleeding in Denmark in the period 2006-2014. Logistic regression analyses were used to investigate the association between treatment with SSRIs and outcome following adjustment for pre-defined confounders. Sensitivity and subgroup analyses were performed to evaluate the validity of the findings. RESULTS: A total of 14 343 patients were included. Following adjustment, treatment with SSRIs was not associated with increased risk of endoscopy-refractory bleeding (odds ratio [OR] [95% Confidence Interval (CI)]: 1.03 [0.79-1.33]), rebleeding (OR [95% CI]: 0.96 [0.83-1.11]) or 30-day mortality (OR [95% CI]: 1.01 [0.85-1.19]. These findings were supported by sensitivity and subgroup analyses. CONCLUSIONS: According to our data, treatment with SSRIs does not influence the risk of endoscopy-refractory bleeding, rebleeding or 30-day mortality in peptic ulcer bleeding.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Laursen SB, Leontiadis GI, Stanley AJ, et al. The use of selective serotonin receptor inhibitors (SSRIs) is not associated with increased risk of endoscopy-refractory bleeding, rebleeding or mortality in peptic ulcer bleeding. Aliment Pharmacol Ther. 2017. PMID: 28543334. doi:10.1111/apt.14153

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。